Cite
Pan Y, Robertson G, Pedersen L, et al. Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2017;8(10):17406doi: 10.18632/oncotarget.15921.
Pan, Y., Robertson, G., Pedersen, L., Lim, E., Hernandez-Herrera, A., Rowat, A. C., Patil, S. L., Chan, C. K., Wen, Y., Zhang, X., Basu-Roy, U., Mansukhani, A., Chu, A., Sipahimalani, P., Bowlby, R., Brooks, D., Thiessen, N., Coarfa, C., Ma, Y., Moore, R. A., Schein, J. E., Mungall, A. J., Liu, J., Pecot, C. V., Sood, A. K., Jones, S. J., Marra, M. A., & Gunaratne, P. H. (2017). Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget, 8(10), 17406. https://doi.org/10.18632/oncotarget.15921
Pan, Yinghong, et al. "Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer." Oncotarget vol. 8,10 (2017): 17406. doi: https://doi.org/10.18632/oncotarget.15921
Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH. Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2017 Mar 07;8(10):17406. doi: 10.18632/oncotarget.15921. PMID: 28403581; PMCID: PMC5370050.
Copy
Download .nbib